GLP-1 dose escalation: why you start low and step up, and what each label says

Type “Ozempic dose schedule” or “how much semaglutide should I take” into a search bar and you’ll find a lot of clean-looking ladders — week 1 this many milligrams, week 5 that many — often sitting right next to a link to buy the drug. That’s the wrong way to read a dose. The schedule on an approved label isn’t a target to sprint toward; it’s a deliberately slow on-ramp, and understanding why it’s slow is more useful than any number on a chart.

This page explains how dose escalation — “titration” — works on these medicines, and reports what the FDA labels actually say. It is not medical advice, and not a schedule to follow on your own. Your dose and its timing are decided with the clinician who prescribes it.

Why the dose starts low and goes up slowly

GLP-1 (and, for tirzepatide, GLP-1/GIP) receptor agonists do part of their job by slowing how fast the stomach empties and acting on the brain’s appetite and nausea pathways. That’s also why the most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation. The good news is that the gut largely adapts to these effects over a few weeks.

Titration is built around that adaptation. The approach begins at a dose too low to do much therapeutically, holds it while the body adapts, then steps up — and repeats. The FDA labels for these medicines state the reason in nearly identical words: “Follow the dosage escalation … to reduce the risk of gastrointestinal adverse reactions” (Wegovy’s says “to minimize” them). In the pivotal weight-loss trial (STEP 1), the researchers built in a fixed 16-week escalation to minimize gastrointestinal side effects, and reported that those events, while common, were mostly transient and mild to moderate.

What the approved labels describe

Read this as a description of how the labels are shaped — not a plan to self-administer. The specific milligram at each step is defined by the label and applied by a prescriber; it is not a sequence to run yourself.

• Semaglutide (Ozempic, Wegovy) begins at a low starting dose and is raised over roughly monthly intervals across several months before a maintenance dose is reached. Wegovy’s weight-management label describes about five escalation steps over roughly four months; Ozempic’s diabetes label raises the dose only conditionally, “if additional glycemic control is needed.”
• Tirzepatide (Mounjaro, Zepbound) likewise begins at a low starting dose and is stepped up no sooner than about monthly toward a maintenance dose, up to a labeled maximum — each increase a prescriber’s decision.

Three principles run through all of them, and they matter more than the specific milligrams: (1) a defined starting dose that is a runway, not a therapeutic target; (2) a minimum interval — generally at least four weeks — before any step up; and (3) increases that are conditional and prescriber-directed (“may be increased,” not “will be increased”).

Why rushing or skipping steps backfires

If the entire point of the schedule is to control GI reactions, then compressing it — jumping a step, or bumping the dose early because progress feels slow — removes the buffer that builds tolerance. The predictable result is more nausea, more vomiting, and the dehydration that can follow. “Faster” is not “better” here; it’s usually just “sicker,” and it’s one reason self-directed dosing from non-prescribed sources — which may also be unsafe or unlawful to obtain — is risky.

The labels also allow the schedule to bend the other way: the weight-management labels describe delaying an increase — or dropping back a step — if a dose isn’t tolerated, again as a decision made with a prescriber. Titration is a two-way dial, not a one-way climb.

Missed doses and long gaps

A single missed weekly dose isn’t an emergency, and each label gives its own rule for it — and they differ even between two versions of the same drug. (We cover the specifics on the missed-dose page: Ozempic within 5 days, Wegovy keyed to whether your next dose is more than 2 days away, Mounjaro and Zepbound within 4 days.) The key principle is that none of the labels have you double up to catch up.

A longer gap is different. Because tolerance to the GI effects fades when you stop, restarting at your old higher dose can bring the early nausea back. After a prolonged break, prescribers commonly re-initiate lower and re-titrate — but exactly how is a clinical judgment for your prescriber, not something to improvise from a web page.

The honest bottom line

Dose escalation on these medicines is one of the best-established things about them: four independent FDA labels and the pivotal trial program all build in the same slow step-up for the same reason — to make the drugs tolerable while your body adapts. What that means for you — which dose, how fast, whether to pause a step — is individualized and belongs with the clinician who prescribes and monitors it. Treat any clean “just follow this schedule” chart, especially one attached to a place selling the drug, as the tell of a page that’s skipped the part that actually keeps you safe.

Frequently asked questions

Why do you start Ozempic at 0.25 mg if it doesn’t cause much weight loss? Because that low dose is a starting dose, not a treatment dose — the label lists 0.25 mg as the initiation dose and reserves the higher steps for glycemic control. Its purpose is to let your body adapt to the drug’s effect on the stomach so that the later, effective doses cause less nausea. It’s a runway, not the flight.

How long does it take to reach the full dose? It depends on the medicine and is decided with your prescriber, but the labels build in a step roughly every four weeks. For semaglutide, the label’s escalation reaches the maintenance dose at around month four; tirzepatide is stepped up no sooner than about every four weeks toward its maintenance dose. This describes the label structure — the exact milligrams and timing are the label’s and your prescriber’s, not a schedule to run yourself.

What happens if you increase the dose too fast? The escalation exists precisely to limit gastrointestinal side effects, so moving faster than the label’s minimum intervals tends to bring more nausea, vomiting and diarrhea, and the dehydration that can follow. It generally doesn’t speed up results — it just makes the ramp harder to tolerate. Dose changes are a prescriber’s decision.

Can I follow one of the dose charts I found online? No — a dose chart isn’t a substitute for a prescription. The numbers on the approved labels are individualized by a clinician who knows your history, your response and your other medicines, and the labels write every increase as a decision made with a prescriber. This is especially important given that compounded or “research” semaglutide and tirzepatide sold for self-dosing are not FDA-approved and come with no verified schedule. This page is educational, not a dosing recommendation.

Do I need to re-titrate if I stopped for a while? Possibly — tolerance to the GI effects fades when you stop, so restarting at a previous higher dose can bring the early side effects back. Prescribers often restart lower and step back up, but the specifics are a clinical decision. Check with your prescriber or pharmacist before restarting after a gap.